Sagamihara, Japan

Masahiro Okada

This inventor holds 1 USPTO granted patent. Top assignees: Brightpath Biotherapeutics Co., Ltd., Kyoto Prefectural Public University Corporation, Shinshu University. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masahiro Okada. Retrieved from https://idiyas.com/inventor/masahiro-okada-ey9anqsr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masahiro Okada: Innovator in Immune Cell Production

Introduction

Masahiro Okada is a notable inventor based in Sagamihara, Japan. He has made significant contributions to the field of immunology, particularly in the production of immune cells. His innovative work has led to the development of a patented method that enhances the capabilities of immune cells.

Latest Patents

Masahiro Okada holds a patent for a method titled "Method for Producing Cell Population Containing CAR-Expressing Immune Cells." This patent represents a crucial advancement in the production of immune cells that can be utilized in various therapeutic applications.

Career Highlights

Throughout his career, Okada has been associated with prestigious institutions such as Shinshu University and Kyoto Prefectural Public University Corporation. His work at these institutions has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Masahiro Okada has worked alongside notable colleagues, including Yozo Nakazawa and Shigeki Yagyu. Their collaborative efforts have furthered the understanding and application of immune cell technology.

Conclusion

Masahiro Okada's contributions to the field of immunology through his innovative patent and collaborations with esteemed colleagues highlight his role as a significant inventor. His work continues to influence advancements in immune cell production and therapy.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…